Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

---

Session 88   Poster Abstracts Mechanisms of Drug Resistance and Increased Susceptibility Tuesday, 1:30 - 3:30 pm Poster Hall

624	Substrate Recognition and Drug Resistance in HIV Protease C Schiffer*, M Prabu-Jeyablan, N King, and E Nalivaika Univ. of Massachusetts Med. Sch., Worcester, USA
625	Recombinant HIV Gag-Pol Proteins Display Unique I50L Phenotype of Selective Atazanavir Resistance and Increased Susceptibility to Other PI S Weinheimer, L Discotto, J Friborg, and R Colonno* Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, USA
626	Increased Excision and Free Access to the Pre-translocation Site of HIV-1 M41L+D67N+L210W+T215Y Mutant RT Mediate Resistance to Tenofovir and AZT K L White*1, B Marchand2, NA Margot1, A S Ray1, R Wang1, M McDermott1, M D Miller1, and M Gotte2 1Gilead Sci., Inc., Foster City, CA, USA and 2McGill Univ. AIDS Ctr., Lady Davis Inst.-Jewish Gen. Hosp., Montreal, Quebec, Canada
627	The K65R Mutation in Tenofovir-naïve Patients: Frequent Association with Q151M Mutation C Amiel*1, A Kara1, V Schneider2, G Pialoux3, W Rozenbaum3, and J C Nicolas1 1Lab. of Virology, Hosp. Tenon, Paris, France; 2Lab. of Virology, Hosp. Tenon, Paris, France; and 3Hosp. Tenon, Paris, France
628	Effect of Interactions of HIV-1 Reverse Transcriptase Inhibitor Drug-resistance Mutations on Phenotypic Drug Sensitivity X Han1, M Montes-Walters1, M Filizzola1, M B Goetz2, W A O'Brien*1, and M R Ferguson1 1Univ. of Texas Med. Branch at Galveston, USA and 2Univ. of California, Los Angeles/VA Greater Los Angeles Healthcare System, USA
629	Expanded range of HIV-1 Reverse Transcriptase Mutations Detected through Long-range Sequencing R Kagan*1, M Winters2, T Merigan2, and P Heseltine1 1Quest Diagnostics, Nichols Inst., San Juan Capistrano, CA, USA and 2Ctr. for AIDS Res., Stanford Univ., CA, USA
630	The Genetic Correlates of NNRTI Hypersusceptibility in 444 Paired Isolates from Nucleoside-experienced Subjects N Shulman*1, R J Bosch2, J Mellors3, M Albrecht4, D Katzenstein1, for the DACS 217 team, and DACS 217 Team 1Stanford Univ. Sch. of Med., CA, USA; 2Harvard Sch. of Publ. Hlth., Boston, MA, USA; 3Univ. of Pittsburgh Sch. of Med., PA, USA; and 4Beth Israel Deaconness Med. Ctr., Boston, MA, USA
631	in vitro NNRTI Resistance Emergence in a Novel RT-SHIV Z Ambrose*, V Boltz, S Palmer, J M Coffin, S H Hughes, and V N KewalRamani NCI, NIH, DHHS, Frederick, MD, USA
632	Multiple Mutations in HIV-1 Integrase Confer Resistance to the Phase 1/2 Clinical Trial Drug S-1360 M Witvrouw*, V Fikkert, B Van Remoortel, B Van Maele, E De Clercq, and Z Debyser Rega Inst. for Med. Res., Katholieke Univ. Leuven, Belgium and The European TRIoH Consortium
633	Resistant Mutations to HIV-1 Fusion Inhibitors Are Restricted by gp41 and Rev Responsive Element Functions E Kodama*1, M Ikeuchi1, N Mabuchi1, A Otaka2, M Ohno1, N Fujii2, and M Matsuoka1 1Inst. for Virus Res., Kyoto Univ., Japan and 2Grad. Sch. of Pharm. Sci., Kyoto Univ., Japan